(Q33365108)

26 July 2017

1 reference

title

Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor (English)

1 reference

26 July 2017

1 reference

Marian P LaMonte

1

1 reference

26 July 2017

Philip M Brown

series ordinal

2

1 reference

26 July 2017

Marcie J Hursting

series ordinal

3

1 reference

26 July 2017

publication date

1 January 2005

1 reference

Expert Review of Cardiovascular Therapy

26 July 2017

published in

1 reference

26 July 2017

volume

3

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

31-41

1 reference

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Treatment of heparin-induced thrombocytopenia: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

How I treat heparin-induced thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Heparin-induced thrombocytopenia: twenty-nine years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Heparin-induced thrombocytopenia: a ten-year retrospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Temporal aspects of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Heparin-induced thrombocytopenia in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Hirudin in renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban dosing in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Heparin-induced thrombocytopenia in coronary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Off-pump coronary artery bypass for a heparin-allergic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban use during pediatric interventional cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.1.31

21 January 2018

Identifiers

DOI

10.1586/14779072.3.1.31

1 reference

26 July 2017

1 reference